| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) (NCT06400264) | National Cancer Institute (NCI) | 2022-02-22 |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (NCT04870944) | Children's Oncology Group | 2022-01-28 |
| Solving Riddles Through Sequencing (NCT05046444) | Munich Leukemia Laboratory | 2022-01-19 |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors (NCT05071209) | National Cancer Institute (NCI) | 2021-12-22 |
| Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies (NCT04994626) | Chinese Academy of Medical Sciences | 2021-10-01 |
| Avo In R/R And Previously Untreated MCL (NCT04855695) | Austin I Kim | 2021-07-02 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study (NCT04500548) | National Cancer Institute (NCI) | 2021-05-11 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04320888) | National Cancer Institute (NCI) | 2021-05-03 |
| Dual Target CAR-T Cells in B-cell Lymphoma (NCT04723914) | YuLi | 2020-10-20 |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas (NCT03925428) | National Cancer Institute (NCI) | 2020-09-18 |
| Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma (NCT05006534) | National Taiwan University Hospital | 2020-06-01 |
| Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) (NCT06400251) | National Cancer Institute (NCI) | 2019-08-08 |
| Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) (NCT06400225) | National Cancer Institute (NCI) | 2019-07-24 |
| Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) (NCT06400238) | National Cancer Institute (NCI) | 2018-10-15 |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) (NCT06308822) | National Cancer Institute (NCI) | 2018-08-20 |
| Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) (NCT05490771) | National Cancer Institute (NCI) | 2018-06-20 |
| Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (NCT03418038) | Mayo Clinic | 2018-03-23 |
| Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (NCT06385483) | National Cancer Institute (NCI) | 2018-02-28 |
| Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma (NCT03323034) | Children's Oncology Group | 2018-01-11 |
| IACS-010759 in Advanced Cancers (NCT03291938) | M.D. Anderson Cancer Center | 2017-11-13 |
| Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) (NCT06390852) | National Cancer Institute (NCI) | 2017-08-21 |
| Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) (NCT04439227) | National Cancer Institute (NCI) | 2017-03-24 |
| Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) (NCT06390839) | National Cancer Institute (NCI) | 2017-03-22 |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) (NCT06390865) | National Cancer Institute (NCI) | 2017-03-12 |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) (NCT06385496) | National Cancer Institute (NCI) | 2017-03-12 |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT02780804) | National Cancer Institute (NCI) | 2017-01-06 |
| Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) (NCT06390826) | National Cancer Institute (NCI) | 2016-11-01 |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) (NCT06357975) | National Cancer Institute (NCI) | 2016-07-29 |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) (NCT06360575) | National Cancer Institute (NCI) | 2016-07-20 |
| Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) (NCT06357988) | National Cancer Institute (NCI) | 2016-06-20 |
| Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) (NCT04439214) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) (NCT04439201) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) (NCT04439123) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) (NCT04439344) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) (NCT04439240) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) (NCT04439149) | National Cancer Institute (NCI) | 2016-05-05 |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) (NCT04439188) | National Cancer Institute (NCI) | 2016-03-21 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) (NCT04439318) | National Cancer Institute (NCI) | 2016-02-25 |
| Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) (NCT04439175) | National Cancer Institute (NCI) | 2016-02-25 |
| Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) (NCT06303167) | National Cancer Institute (NCI) | 2016-01-08 |
| Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) (NCT04439292) | National Cancer Institute (NCI) | 2016-01-04 |
| Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) (NCT04439331) | National Cancer Institute (NCI) | 2015-11-19 |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas (NCT02323880) | Children's Oncology Group | 2015-10-30 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) (NCT04439136) | National Cancer Institute (NCI) | 2015-08-12 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) (NCT04439279) | National Cancer Institute (NCI) | 2015-08-12 |
| Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) (NCT04439110) | National Cancer Institute (NCI) | 2015-08-12 |
| Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) (NCT04439253) | National Cancer Institute (NCI) | 2015-08-12 |
| Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours (NCT02343718) | Canadian Cancer Trials Group | 2015-06-24 |
| Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma (NCT01742988) | Curis, Inc. | 2012-12-01 |